Armacokinetic profile. Translation in two advanced BC sufferers, resulted in no unwanted side effects, confirming preceding observations on the biosafety of radiotracers according to the potent GRPR-antagonist [DPhe6 ,LeuNHEt13 ]BBN(6-13) and on GRPR-antagonist radioligands in general. Moreover, it revealed the ability of [99m Tc]Tc-DB15 to detect a number of metastatic BC lesions, each within the skeleton and in soft tissues, but these findings must be confirmed prospectively in a committed human study. In view on the above, further clinical evaluation seems to become warranted to establish the diagnostic value of [99m Tc]Tc-DB15 in BC, Computer, and other GRPR-expressing human malignancies.Supplementary Materials: The following are offered on line at https://www.mdpi.com/article/ 10.3390/cancers13205093/s1, Figure S1: Typical radiochromatogram of HPLC analysis of [99m Tc]TcDB15 (preclinical); Figure S2: Typical radiochromatogram of HPLC evaluation of [99m Tc]Tc-DB15 (for patients); Figure S3: Entire physique scan 3 h pi of [99m Tc]Tc-DB15 in patient 1 (with anterior and posterior projection); Figure S4: PET/CT 1 h pi of [18 F]FDG in patient 1; Table S1: Numerical biodistribution data for [99m Tc]Tc-DB15 in PC-3 xenograft-bearing SCID mice at 1, four and 24 h pi; Table S2: Numerical biodistribution information for [99m Tc]Tc-DB15 in T-47D xenograft-bearing SCID mice at 1, four and 24 h pi.Cancers 2021, 13,12 ofAuthor Contributions: Conceptualization, B.A.N., R.M. and T.M.; methodology, B.A.N., A.K., P.K., B.J., B.B., D.I. and T.M.; validation, B.A.N., R.M., R.C., D.I. and T.M.; investigation, B.A.N., A.K., P.K., B.J., B.B., R.C., D.I. and T.M.; sources, R.M., R.C. and T.M.; information curation, P.K., R.M., R.C. and T.M.; writing–original draft preparation, T.M.; writing–review and editing, all co-authors; supervision, B.A.N., R.M., R.C. and T.M.; project administration, R.M., R.C. and T.M.; funding acquisition, R.M., R.C. and T.M. All authors have study and agreed towards the published version in the manuscript. Funding: The preclinical study was co-financed by Greece as well as the European Union (European Regional Development Fund) by way of the project “NCSRD–INRASTES study activities within the framework with the national RIS3” (MIS 5002559), implemented beneath the “Action for the Strategic Improvement on the Study and Technological Sector”, CMP-Sialic acid sodium salt MedChemExpress funded by the Operational Program “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020). Additional assistance was supplied by Siemens AG via the project stablishing a Multidisciplinary and Powerful Innovation and Entrepreneurship Hub(E-11928). The preparation with the radioligand for the patient study was supported by the CERAD project, financed beneath Smart Development Operational System 2014020, Priority IV, Measure four.2. POIR.04.02.004-A001/16. The clinical a part of the study obtained financial support in the Poznan University of Healthcare Sciences (grant No. 502-14-22213550-41147). Institutional Overview Board Trimetazidine Purity Statement: The animal and patient studies had been conducted in accordance with the suggestions on the Declaration of Helsinki. The animal protocols have been authorized by the Department of Agriculture and Veterinary Service with the Prefecture of Athens (protocol numbers #1609 for the stability and #1610 for the biodistribution studies, both issued on 11 April 2018). The patient study protocol was approved by the Bioethical Committee from the Poznan University of Healthcare Sciences (selection no. 1153 issued on 16 January 2020). Informed Consent Statement: Patients gave th.
